Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes

Abstract

Purpose To evaluate the efficacy and safety of photodynamic therapy (PDT) with halfdose verteporfin in patients with chronic central serous chorioretinopathy (CCSC) and retinal functional changes, by functional acuity contrast test (FACT). Methods In this study, 27 eyes of 24 patients with CCSC were treated with PDT with halfdose verteporfin. Best-corrected visual acuity (BCVA), central foveal thickness (CFT) and resolution of subretinal fluid on optical coherence tomography (OCT), and leakage on fluorescein angiography (FA) and indocyanine green angiography (ICGA) were assessed. Contrast sensitivity test was performed at baseline and at 12th month for investigating retinal functional changes. Results The mean follow-up period was 25.33 ± 11.08 months. The mean age was 43.7±8.6 years. Seventeen patients were male (70.8%) and seven patients were female (29.2%). Post PDT at 1st, 3rd, 6th, 12th month and at last follow-up, BCVA were significantly improved compared with the baseline BCVA (Po0.001), and CFT post PDT were significantly thinner than the baseline measurement (Po0.001). There was significant difference between pre-and post-PDT 12th month contrast sensitivities at all five different spatial frequency channels (Po0.01). Conclusions Half-dose PDT is an effective and safe method in the treatment of CCSC with anatomical and functional success. The measurement of contrast sensitivity by FACT can be useful for evaluating the functional effectiveness of half-dose PDT for CCSC.

The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case–control study

“…Duration of symptoms, initial BCVA, and integrity of the foveal IS/OS line were reported to be related to final visual outcomes in previous studies. [19][20][21] There is also emerging evidence that early resolution of SRF could reduce the risk of photoreceptor/ RPE degeneration and improve visual acuity. 22 However, in our study, despite the shorter resolution time in spontaneously resolved group, no difference was found between the groups in respect to the visual acuity changes during follow up.…”

Photodynamic therapy: current role in the treatment of chorioretinal conditions

“…Half-dose vPDT therapy uses a verteporfin dosage of 3 mg/m 2 BSA. 13,[48][49][50][51][52] Reduced fluence vPDT therapy uses a vPDT laser fluence of 25 J/cm 2 (300 mW/cm 2 for 83 s). 14,15,53,54 There is limited evidence to compare these different vPDT protocols for CSC in the absence of randomised controlled trials.…”

Repeatability of contrast sensitivity testing in patients with age-related macular degeneration, glaucoma, and cataract

“…Glaucoma, cataract, and AMD patients suffer from pro blems in vision-related activities of daily living and the inability to recognize targets in real world, which can be better identified by CS tests than by visual acuity tests (14,(16)(17)(18) . The increasing importance of visual quality and the need for accurate measurement of visual acuity has led to more interest in CS tests (12,(19)(20)(21) . There are several clinical tests for measuring CS with letters or gratings (5,(22)(23)(24)(25)(26) .…”

“…Keywords: Macular degeneration; Contrast sensitivity; Glaucoma; Age effect; Repro ducibility of results , glaucoma, catarata e AMD foram, respectivamente, ICC 0,87; 0,90; 0,76; 0,69, e COR 0,24; 0,20; 0,38; 0,25 …”

“…Conclusion: In subjects with good visual acuity, the FVA system is useful for evaluating CS and demonstrates good repeatability, as shown by ICC and COR. Because there is no ceiling effect, this system is beneficial for evaluation of early changes in CS, particularly in patients with glaucoma or AMD.Keywords: Macular degeneration; Contrast sensitivity; Glaucoma; Age effect; Repro ducibility of results , glaucoma, catarata e AMD foram, respectivamente, ICC 0,87; 0,90; 0,76; 0,69, e COR 0,24; 0,20; 0,38; 0,25 …”